JP5286287B2 - 骨発達を促進するための組成物及び方法 - Google Patents
骨発達を促進するための組成物及び方法 Download PDFInfo
- Publication number
- JP5286287B2 JP5286287B2 JP2009551047A JP2009551047A JP5286287B2 JP 5286287 B2 JP5286287 B2 JP 5286287B2 JP 2009551047 A JP2009551047 A JP 2009551047A JP 2009551047 A JP2009551047 A JP 2009551047A JP 5286287 B2 JP5286287 B2 JP 5286287B2
- Authority
- JP
- Japan
- Prior art keywords
- composition
- ppm
- fed
- feline
- animal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims description 168
- 238000000034 method Methods 0.000 title claims description 63
- 230000001737 promoting effect Effects 0.000 title claims description 11
- 230000014461 bone development Effects 0.000 title description 8
- 241001465754 Metazoa Species 0.000 claims description 57
- 235000013305 food Nutrition 0.000 claims description 26
- 210000000988 bone and bone Anatomy 0.000 claims description 22
- 241000282326 Felis catus Species 0.000 claims description 21
- 241000282324 Felis Species 0.000 claims description 16
- 230000035935 pregnancy Effects 0.000 claims description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 10
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 8
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 7
- 239000004472 Lysine Substances 0.000 claims description 7
- 229930182817 methionine Natural products 0.000 claims description 7
- 230000011164 ossification Effects 0.000 claims description 7
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 5
- 229930003268 Vitamin C Natural products 0.000 claims description 5
- 229960004203 carnitine Drugs 0.000 claims description 5
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 5
- 229960001231 choline Drugs 0.000 claims description 5
- 235000019154 vitamin C Nutrition 0.000 claims description 5
- 239000011718 vitamin C Substances 0.000 claims description 5
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims description 4
- 229930003427 Vitamin E Natural products 0.000 claims description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 4
- 229910052748 manganese Inorganic materials 0.000 claims description 4
- 239000011572 manganese Substances 0.000 claims description 4
- 235000019165 vitamin E Nutrition 0.000 claims description 4
- 229940046009 vitamin E Drugs 0.000 claims description 4
- 239000011709 vitamin E Substances 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 2
- 235000020778 linoleic acid Nutrition 0.000 claims description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 2
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000009472 formulation Methods 0.000 description 28
- 239000013065 commercial product Substances 0.000 description 13
- 235000020776 essential amino acid Nutrition 0.000 description 13
- 239000003797 essential amino acid Substances 0.000 description 13
- 230000012010 growth Effects 0.000 description 13
- 239000004615 ingredient Substances 0.000 description 11
- 239000011707 mineral Substances 0.000 description 9
- 235000010755 mineral Nutrition 0.000 description 9
- 229910052500 inorganic mineral Inorganic materials 0.000 description 8
- 235000015097 nutrients Nutrition 0.000 description 8
- 241000894007 species Species 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 6
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108010022452 Collagen Type I Proteins 0.000 description 4
- 102000012422 Collagen Type I Human genes 0.000 description 4
- 238000000692 Student's t-test Methods 0.000 description 4
- 230000031018 biological processes and functions Effects 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 239000003925 fat Substances 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000037231 joint health Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000012353 t test Methods 0.000 description 4
- 208000006386 Bone Resorption Diseases 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000037180 bone health Effects 0.000 description 3
- 230000024279 bone resorption Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 235000001465 calcium Nutrition 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 235000020774 essential nutrients Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000000384 rearing effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 229960003080 taurine Drugs 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 2
- ZAHDXEIQWWLQQL-IHRRRGAJSA-N Deoxypyridinoline Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(O)=C(C[C@H](N)C([O-])=O)C(CC[C@H](N)C(O)=O)=C1 ZAHDXEIQWWLQQL-IHRRRGAJSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000008416 bone turnover Effects 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 235000014786 phosphorus Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 235000011649 selenium Nutrition 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010023204 Joint dislocation Diseases 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- LOJFGJZQOKTUBR-XAQOOIOESA-N NC(N)=NCCC[C@@H](C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCC(O)=O)C)CC1=CN=CN1 Chemical group NC(N)=NCCC[C@@H](C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCC(O)=O)C)CC1=CN=CN1 LOJFGJZQOKTUBR-XAQOOIOESA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 206010049088 Osteopenia Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- LCYXYLLJXMAEMT-SAXRGWBVSA-N Pyridinoline Chemical compound OC(=O)[C@@H](N)CCC1=C[N+](C[C@H](O)CC[C@H](N)C([O-])=O)=CC(O)=C1C[C@H](N)C(O)=O LCYXYLLJXMAEMT-SAXRGWBVSA-N 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960001570 ademetionine Drugs 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000004251 balanced diet Nutrition 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 230000010256 bone deposition Effects 0.000 description 1
- 230000018678 bone mineralization Effects 0.000 description 1
- 229940112869 bone morphogenetic protein Drugs 0.000 description 1
- 230000037118 bone strength Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- 108010049937 collagen type I trimeric cross-linked peptide Proteins 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- QUQFTIVBFKLPCL-UHFFFAOYSA-L copper;2-amino-3-[(2-amino-2-carboxylatoethyl)disulfanyl]propanoate Chemical compound [Cu+2].[O-]C(=O)C(N)CSSCC(N)C([O-])=O QUQFTIVBFKLPCL-UHFFFAOYSA-L 0.000 description 1
- 150000001944 cysteine derivatives Chemical class 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000034435 immune system development Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000001055 magnesium Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000008271 nervous system development Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000006180 nutrition needs Nutrition 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000007686 potassium Nutrition 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 229940091258 selenium supplement Drugs 0.000 description 1
- 230000009645 skeletal growth Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 235000003687 soy isoflavones Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 230000008354 tissue degradation Effects 0.000 description 1
- 229930003802 tocotrienol Natural products 0.000 description 1
- 239000011731 tocotrienol Substances 0.000 description 1
- 235000019148 tocotrienols Nutrition 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/105—Aliphatic or alicyclic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/174—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
- A23K20/30—Oligoelements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Birds (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Child & Adolescent Psychology (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
[0001] 本出願は、その内容が参照により本明細書に組み込まれる、米国仮特許出願番号60/891,171(2007年2月22日出願)、及びPCT/US2008/054796(2008年2月22日出願)に対する優先権を主張する。
[0008] 本発明には、
約0.1%〜約0.7%のEPA;
約50ppm〜約200ppmのマンガン;及び
約0.5%〜約1.60%のメチオニンを含んでなる、動物において骨発達を促進するのに有用なペット食品組成物、「組成物1.0」が含まれる。
「組成物1.1」 約0.1%〜約0.7%のDHA、例えば、約0.1%〜約0.5%若しくは0.6%、例えば、約0.2%、約0.3%、又は約0.4%のDHAを含んでなる「組成物1.0」;
「組成物1.2」 約200〜約1200IU/kgのビタミンE、例えば、約500IU/kg〜約1100IU/kg、約700、約800、約900、又は約1000IU/kgのビタミンEを含んでなる「組成物1.0」又は「組成物1.1」;
「組成物1.3」 約50〜約500ppmのビタミンC、例えば、約100〜約400ppmのビタミンC、例えば、約150、約175、約200、又は約225ppmのビタミンCを含んでなる、「組成物1.0」〜「組成物1.2」のいずれかの組成物;
「組成物1.4」 約100ppm〜約500ppmのカルニチン、例えば、約200、約300、又は約400ppmのカルニチンを含んでなる、「組成物1.0」〜「組成物1.3」のいずれかの組成物;
「組成物1.5」 約2.5g/1000kcal〜約7g/1000kcalのリジンを含んでなる、「組成物1.0」〜「組成物1.4」のいずれかの組成物;
「組成物1.6」 約2400ppm〜約7500ppmのコリン、例えば、約3000、約4000、約4500、約4600、約4625、約4650、約4700、約5000、又は約6000ppmのコリンを含んでなる、「組成物1.0」〜「組成物1.5」のいずれかの組成物;
「組成物1.7」 約0.1%〜約0.6%のEPA、例えば、約0.2%、約0.3%、約0.4%、又は約0.5%のEPAを含んでなる、「組成物1.0」〜「組成物1.6」のいずれかの組成物;
「組成物1.8」 約50ppm〜約150ppmのマンガンを含んでなる、「組成物1.0」〜「組成物1.7」のいずれかの組成物;
「組成物1.9」 約0.8%〜約1.6%のメチオニン、例えば、約1.3又は約1.4%のメチオニンを含んでなる、「組成物1.0」〜「組成物1.8」のいずれかの組成物。
0〜約90重量%の炭水化物;
約5〜約70重量%のタンパク質;
約2〜約50重量%の脂肪;
約0.1〜約20重量%の総食物繊維;
0〜約15重量%、又は約2〜約8重量%のビタミン、ミネラルと、動物の栄養必要量を支える多様な百分率における他の栄養素。
「組成物1.12」 約20〜約60重量%のタンパク質、例えば、約30〜約55重量%のタンパク質を含んでなる、「組成物1.10」又は「組成物1.11」;
「組成物1.13」 約5〜約40重量%の脂肪、例えば、少なくとも約8%又は約9%〜約40%の脂肪を含んでなる、「組成物1.10」〜「組成物1.12」のいずれか1つの組成物;
「組成物1.14」 約1〜約11重量%の総食物繊維を含んでなる、「組成物1.10」〜「組成物1.13」のいずれか1つの組成物;
「組成物1.15」 約1000〜約4000ppmのタウリンを含んでなる、「組成物1.0」〜「組成物1.14」のいずれかの組成物;
「組成物1.16」 約0.5%〜約6.0%のリノール酸、例えば、約2.5%〜約5%のリノール酸を含んでなる、「組成物1.0」〜「組成物1.15」のいずれかの組成物;
「組成物1.17」 約1%〜約3%の総n−3脂肪酸、例えば、約1.3%、約1.4%、約1.5%、又は約1.6%の総n−3脂肪酸を含んでなる、「組成物1.0」〜「組成物1.16」のいずれかの組成物;
「組成物1.18」 約1%〜約6%の総n−6脂肪酸、例えば、3%〜5%、約3.5%、又は約4%の総n−6脂肪酸を含んでなる、「組成物1.0」〜「組成物1.17」のいずれかの組成物。
[0011] 本発明には、「組成物1.0」〜「組成物1.18」のいずれか1つをネコ科動物へ投与することを含んでなる、該ネコ科動物において骨発達及び/又は関節健康を促進する方法、「方法2.0」が含まれる。
「方法2.1」 ネコ科動物が仔猫である、「方法2.0」の方法。
「方法2.2」 ネコ科動物が、「組成物1.0」〜「組成物1.18」のいずれか1つを妊娠期に給餌した母猫(a queen)より産まれたものである、「方法2.0」又は「方法2.1」の方法。
「方法2.4」 「組成物1.0」〜「組成物1.18」のいずれか1つを妊娠前に母猫へ給餌する、「方法2.2」の方法。
「方法2.6」 「組成物1.0」〜「組成物1.18」のいずれか1つより本質的になる組成物を妊娠の前とその間に母猫へ給餌する、「方法2.2」〜「方法2.5」のいずれか1つの方法。
「方法2.9」 「組成物1.0」〜「組成物1.18」のいずれか1つからなる食品組成物を仔猫へ給餌する、「方法2.8」の方法。
「方法2.11」 組成物を有効期間動物へ投与する、「方法2.0」〜「方法2.10」のいずれか1つの方法。
[0013] また、本明細書に開示する組成物を成長期の動物へ、例えば、成長期の仔犬又は仔猫へ直接投与することに加えて、本組成物は、動物がまだ子宮内にある間、又は動物が乳幼児である間に動物の母獣へ投与してよいと考慮される。
[0023] 本明細書に使用するように、用語「仔猫」は、典型的には誕生と12ヶ月の間の年齢の未熟なネコ科動物を意味する。
[0035] 成長期の動物の発育を強化するための製剤を本明細書において以下に開示する。これらの組成物は、「理想のタンパク質コンセプト」(Baker and Czarnecki-Maulden, 1991 Annu. Rev. Nutr. 11: 239-63)を考慮に容れて開発されている。
[0037] 試験には、4種の食品:実験製剤X、市販品A、市販品A1、及び市販品Bを使用する。この食品の組成を表2に提示する。市販品A、A1、及びBの食品は、市販の供給源より入手可能である。市販品A及びA1は、同じブランドの食品であるが、異なるロットで生産されている。
Claims (17)
- 動物において骨形成を促進するためのペット食品組成物であって、
0.1%〜0.7%のEPA;
0.1%〜0.7%のDHA;
2.5%〜5.0%のリノール酸;
1%〜3%の総n−3脂肪酸;
200〜1200IU/kgのビタミンE;
50〜500ppmのビタミンC;
50ppm〜200ppmのマンガン;及び
0.5%〜1.6%のメチオニン
を含んでなる、前記ペット食品組成物。 - 100ppm〜500ppmのカルニチンを含んでなる、請求項1の組成物。
- 2.5g/1000kcal〜7g/1000kcalのリジンを含んでなる、請求項1又は2の組成物。
- 2400ppm〜7500ppmのコリンを含んでなる、請求項1〜3のいずれか1項の組成物。
- 0.1%〜0.6%のEPAを含んでなる、請求項1〜4のいずれか1項の組成物。
- 50ppm〜150ppmのマンガンを含んでなる、請求項1〜5のいずれか1項の組成物。
- 0.8%〜1.6%のメチオニンを含んでなる、請求項1〜6のいずれか1項の組成物。
- 請求項1〜7のいずれか1項のペット食品組成物をネコ科動物へ、または該ネコ科動物が子宮内にいる間に該ネコ科動物の母猫へ投与することを含んでなる、該ネコ科動物において骨形成を促進する方法。
- ネコ科動物が仔猫である、請求項8の方法。
- ネコ科動物が、請求項1〜7のいずれか1項の組成物を給餌した母猫(a queen)より産まれたものである、請求項8又は9の方法。
- ネコ科動物が子宮内にいる、請求項10の方法。
- 請求項1〜7のいずれか1項に記載の組成物を妊娠前に母猫へ給餌する、請求項10又は11のいずれか1項の方法。
- 請求項1〜7のいずれか1項に記載の組成物を妊娠期間の大部分の間母猫へ給餌する、請求項10〜12のいずれか1項の方法。
- 本質的に請求項1〜7のいずれか1項に記載の組成物のいずれか1つからなる組成物を妊娠の前とその間に母猫へ給餌する、請求項10〜13に記載の方法。
- 請求項1〜7のいずれか1項に記載の組成物を離乳前に仔猫へ給餌する、請求項8〜14のいずれか1項の方法。
- 請求項1〜7のいずれか1項に記載の組成物を離乳後に仔猫へ給餌する、請求項8〜15のいずれか1項の方法。
- 請求項1〜7のいずれか1項の組成物を哺乳動物へ投与することを含んでなる、骨アルカリホスファターゼを阻害することによって骨形成を促進する方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US89117107P | 2007-02-22 | 2007-02-22 | |
US60/891,171 | 2007-02-22 | ||
PCT/US2008/054796 WO2008103956A1 (en) | 2007-02-22 | 2008-02-22 | Compositions and methods for promoting bone development |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2010518867A JP2010518867A (ja) | 2010-06-03 |
JP2010518867A5 JP2010518867A5 (ja) | 2011-01-06 |
JP5286287B2 true JP5286287B2 (ja) | 2013-09-11 |
Family
ID=39563552
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009551047A Expired - Fee Related JP5286287B2 (ja) | 2007-02-22 | 2008-02-22 | 骨発達を促進するための組成物及び方法 |
JP2009551040A Active JP5474570B2 (ja) | 2007-02-22 | 2008-02-22 | 成長する動物の発育を促進するための組成物と方法 |
JP2009551043A Expired - Fee Related JP5286286B2 (ja) | 2007-02-22 | 2008-02-22 | 神経的発達を強化するための組成物と方法 |
JP2009551045A Active JP5285625B2 (ja) | 2007-02-22 | 2008-02-22 | ネコ科動物の免疫系を強化するための組成物及び方法 |
JP2009551049A Active JP5474571B2 (ja) | 2007-02-22 | 2008-02-22 | 遺伝子発現を変化させるための組成物および方法 |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009551040A Active JP5474570B2 (ja) | 2007-02-22 | 2008-02-22 | 成長する動物の発育を促進するための組成物と方法 |
JP2009551043A Expired - Fee Related JP5286286B2 (ja) | 2007-02-22 | 2008-02-22 | 神経的発達を強化するための組成物と方法 |
JP2009551045A Active JP5285625B2 (ja) | 2007-02-22 | 2008-02-22 | ネコ科動物の免疫系を強化するための組成物及び方法 |
JP2009551049A Active JP5474571B2 (ja) | 2007-02-22 | 2008-02-22 | 遺伝子発現を変化させるための組成物および方法 |
Country Status (12)
Country | Link |
---|---|
US (6) | US20110059202A1 (ja) |
EP (5) | EP2124612B1 (ja) |
JP (5) | JP5286287B2 (ja) |
CN (6) | CN101662951A (ja) |
AU (5) | AU2008218195C1 (ja) |
BR (5) | BRPI0807372A2 (ja) |
CA (5) | CA2679682C (ja) |
DK (1) | DK2129237T3 (ja) |
ES (1) | ES2546284T3 (ja) |
RU (5) | RU2427278C2 (ja) |
WO (5) | WO2008118586A1 (ja) |
ZA (5) | ZA200906390B (ja) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7872102B2 (en) * | 2005-08-25 | 2011-01-18 | Eli Lilly And Company | Anti-IL-23 antibodies |
BRPI0807372A2 (pt) * | 2007-02-22 | 2014-05-06 | Hills Pet Nutrition Inc | Composição de ração de animal de estimação, e, método para intensificar o desenvolvimento neurológico de um felino. |
EP2367547B1 (en) * | 2008-12-12 | 2014-07-30 | Cognite AB | L-lysine for improving normal cognitive functions |
CA2785646C (en) * | 2009-12-29 | 2016-10-18 | Hill's Pet Nutrition, Inc. | Compositions including ginger for the amelioration or prevention of inflammatory conditions |
CA2797539C (en) * | 2010-05-12 | 2016-07-05 | Hill's Pet Nutrition, Inc. | Methods of diagnosis, control and prophylaxis of inflammation and mitigation of inflammatory conditions in felines |
US20130273196A1 (en) * | 2010-12-20 | 2013-10-17 | Hill's Pet Nutrition, Inc | Pet Food Compositions for Inducing a Satiety Response |
CN103458891A (zh) * | 2011-04-13 | 2013-12-18 | 味之素株式会社 | 营养组合物 |
US8828426B2 (en) | 2011-06-07 | 2014-09-09 | Zx Pharma, Llc | Multiparticulate L-carnitine compositions and related methods |
AU2012355775B2 (en) | 2011-12-19 | 2015-10-08 | Hill's Pet Nutrition, Inc. | Compositions and methods for diagnosing and treating hyperthyroidism in companion animals |
CN103315187B (zh) * | 2013-07-17 | 2014-11-05 | 江苏桂龙生物技术有限公司 | 一种预防宠物骨骼性疾病的饲料 |
CN104026401B (zh) * | 2014-06-10 | 2016-04-27 | 务川县绿之源农业技术推广中心 | 一种小型幼犬粮 |
WO2016067804A1 (ja) * | 2014-10-30 | 2016-05-06 | 不二製油グループ本社株式会社 | 長鎖多価不飽和脂肪酸含有油脂およびそれを含有する食品 |
GB201522300D0 (en) * | 2015-12-17 | 2016-02-03 | Mars Inc | Puppy growth food product |
WO2018109670A1 (en) | 2016-12-15 | 2018-06-21 | Nestec Sa | Compositions and methods that modulate vitamin d and bone mineral content in a companion animal |
WO2018109672A1 (en) | 2016-12-15 | 2018-06-21 | Nestec Sa | Compositions and methods for small canines |
WO2018219877A1 (en) * | 2017-05-29 | 2018-12-06 | Nestec S.A. | Medium chain fatty acids for use in the prevention or treatment of cardiac enlargement and/or valvular heart disease |
WO2019155336A1 (en) * | 2018-02-08 | 2019-08-15 | Societe Des Produits Nestle S.A. | Mct-based nutrition blend for providing health benefits in companion animals |
CN108244374A (zh) * | 2018-02-27 | 2018-07-06 | 佛山市雷米高动物营养保健科技有限公司 | 猫用营养粉剂及其制备方法 |
CA3128189A1 (en) | 2019-02-01 | 2020-08-06 | Mars, Incorporated | Feline food composition |
CN110537630A (zh) * | 2019-09-09 | 2019-12-06 | 天津农学院 | 1,2二硫戊环-3-戊酸的应用、幼犬鲜粮和延长幼犬鲜粮贮藏期的方法 |
EP4040992A1 (en) * | 2019-12-19 | 2022-08-17 | Société des Produits Nestlé S.A. | Compositions and methods for providing a health benefit to a growing animal |
EP4202564A1 (fr) | 2021-12-22 | 2023-06-28 | The Swatch Group Research and Development Ltd | Mouvement mecanique horloger comprenant un balancier pivote magnetiquement |
WO2023150389A1 (en) * | 2022-02-07 | 2023-08-10 | Cornell University | Compositions and methods for increasing dha availability |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4267195A (en) * | 1976-09-10 | 1981-05-12 | University Of Texas | Dog food flavors |
US4130651A (en) * | 1978-03-31 | 1978-12-19 | American Cyanamid Company | Butamisole injectable formulations having improved margin of safety in dogs |
JPH0625057B2 (ja) | 1987-12-14 | 1994-04-06 | 日本油脂株式会社 | 骨形成促進剤 |
JPH04166039A (ja) | 1990-10-26 | 1992-06-11 | Hirotoshi Yokura | ペットフード |
US5690988A (en) * | 1996-02-02 | 1997-11-25 | Colgate Palmolive Company | Pet food composition of improved palatability and a method of enhancing the palatability of a food composition |
US5851573A (en) * | 1997-04-29 | 1998-12-22 | The Iams Company | Pet food composition for large breed puppies and method for promoting proper skeletal growth |
US6156355A (en) * | 1998-11-02 | 2000-12-05 | Star-Kist Foods, Inc. | Breed-specific canine food formulations |
NZ527924A (en) | 1999-01-29 | 2005-01-28 | Mars Uk Ltd | Antioxidant compositions and methods for companion animals |
GB2367489B (en) * | 2000-07-31 | 2005-02-09 | Mars Inc | Use of antioxidants |
US6071544A (en) | 1999-04-01 | 2000-06-06 | The Iams Company | Dietary compositions and method for promoting healthy weight loss cats |
KR20020005050A (ko) * | 1999-05-27 | 2002-01-16 | 디 아이암즈 캄파니 | 산화방지제의 배합물을 이용하여 애완 동물의 면역 반응을증강시키기 위한 방법 및 제품 |
EG22407A (en) | 2000-02-17 | 2003-01-29 | Iams Company | Method for improving bone modeling and chondrocyte functioning in growing canines |
GB2367487A (en) | 2000-10-04 | 2002-04-10 | John Kennedy Mcmillan | Tooth cleaner |
ES2311482T3 (es) | 2000-12-29 | 2009-02-16 | Martin Francis Gannon | Producto alimenticio para animales. |
US6582752B2 (en) | 2001-11-02 | 2003-06-24 | Nestec, Ltd | Methods and compositions for a gender specific diet for puppies |
MXPA05000505A (es) | 2002-07-12 | 2005-07-22 | Iams Company | Efecto sinergetico de la dieta y la interaccion humana en el comportamiento de perros. |
JPWO2004008196A1 (ja) * | 2002-07-13 | 2005-11-10 | 有限会社オートクローニング・テクノロジー | 偏光解析装置 |
EP1524912A1 (en) * | 2002-07-26 | 2005-04-27 | DSM IP Assets B.V. | Compositions comprising lactoferrin |
CA2518197A1 (en) * | 2003-03-07 | 2004-09-23 | Advanced Bionutrition Corporation | Feed formulation for terrestrial and aquatic animals |
WO2004095940A1 (en) * | 2003-04-25 | 2004-11-11 | The University Of Newcastle | Biomass containing animal feed |
WO2005006877A1 (en) * | 2003-07-03 | 2005-01-27 | Hill's Pet Nutrition, Inc. | Compositions and methods for decreasing age-related deterioration in metal activities in companion animals |
EP1641352B2 (en) | 2003-07-07 | 2019-06-19 | Hill's Pet Nutrition, Inc. | Compositions for improved oxidative status in cats |
US8128956B2 (en) * | 2003-09-12 | 2012-03-06 | Mars, Inc. | Food product for hairball treatment |
US8921422B2 (en) * | 2003-10-01 | 2014-12-30 | The Iams Company | Methods and kits for enhancing ability to learn in a puppy or kitten |
US20050266051A1 (en) * | 2004-05-27 | 2005-12-01 | The Procter & Gamble Company | Pet food compositions and methods |
AU2005280008B2 (en) * | 2004-08-30 | 2011-06-16 | Hill's Pet Nutrition, Inc. | Genome-based diet design |
CN1631207A (zh) | 2004-12-03 | 2005-06-29 | 王志文 | 能改善猫狗皮毛质量的不饱和脂肪酸饲料添加剂及饲料 |
DK1838169T3 (en) * | 2004-12-30 | 2016-08-15 | Hills Pet Nutrition Inc | Methods for improving the quality of life of a growing animal |
EP1830629A4 (en) * | 2004-12-30 | 2008-08-27 | Hills Pet Nutrition Inc | METHODS FOR ENHANCING THE QUALITY OF LIFE OF AN ANIMAL AGE |
EP1928552A2 (en) * | 2005-09-30 | 2008-06-11 | Nestec S.A. | Methods and compositions for improving cognitive function |
ES2383094T3 (es) * | 2006-01-10 | 2012-06-18 | Hill's Pet Nutrition, Inc. | Composiciones y método para promover la pérdida de grasa |
AU2007282912A1 (en) * | 2006-08-09 | 2008-02-14 | The Iams Company | Methods of improving bone health and muscle health |
BRPI0807372A2 (pt) * | 2007-02-22 | 2014-05-06 | Hills Pet Nutrition Inc | Composição de ração de animal de estimação, e, método para intensificar o desenvolvimento neurológico de um felino. |
-
2008
- 2008-02-22 BR BRPI0807372-4A patent/BRPI0807372A2/pt not_active Application Discontinuation
- 2008-02-22 JP JP2009551047A patent/JP5286287B2/ja not_active Expired - Fee Related
- 2008-02-22 AU AU2008218195A patent/AU2008218195C1/en not_active Ceased
- 2008-02-22 RU RU2009135261/13A patent/RU2427278C2/ru not_active IP Right Cessation
- 2008-02-22 JP JP2009551040A patent/JP5474570B2/ja active Active
- 2008-02-22 RU RU2009135260/15A patent/RU2441394C2/ru not_active IP Right Cessation
- 2008-02-22 BR BRPI0807373-2A patent/BRPI0807373A2/pt active Search and Examination
- 2008-02-22 CA CA2679682A patent/CA2679682C/en not_active Expired - Fee Related
- 2008-02-22 EP EP08743532.7A patent/EP2124612B1/en active Active
- 2008-02-22 CN CN200880012951A patent/CN101662951A/zh active Pending
- 2008-02-22 CA CA2678938A patent/CA2678938C/en active Active
- 2008-02-22 RU RU2009135263/13A patent/RU2435435C2/ru not_active IP Right Cessation
- 2008-02-22 CA CA2679215A patent/CA2679215C/en not_active Expired - Fee Related
- 2008-02-22 AU AU2008218187A patent/AU2008218187C1/en active Active
- 2008-02-22 US US12/528,137 patent/US20110059202A1/en not_active Abandoned
- 2008-02-22 CN CN200880013110.4A patent/CN101686712B/zh not_active Expired - Fee Related
- 2008-02-22 EP EP08730556.1A patent/EP2112889B1/en not_active Not-in-force
- 2008-02-22 CN CN201410643425.4A patent/CN104472871A/zh active Pending
- 2008-02-22 CA CA2679065A patent/CA2679065C/en not_active Expired - Fee Related
- 2008-02-22 AU AU2008218193A patent/AU2008218193B2/en not_active Ceased
- 2008-02-22 EP EP08730573.6A patent/EP2124611B1/en not_active Not-in-force
- 2008-02-22 US US12/528,164 patent/US9888709B2/en active Active
- 2008-02-22 RU RU2009135245/13A patent/RU2412611C1/ru not_active IP Right Cessation
- 2008-02-22 EP EP08730572.8A patent/EP2129237B1/en not_active Not-in-force
- 2008-02-22 JP JP2009551043A patent/JP5286286B2/ja not_active Expired - Fee Related
- 2008-02-22 AU AU2008231241A patent/AU2008231241B2/en not_active Ceased
- 2008-02-22 BR BRPI0807789-4A2A patent/BRPI0807789A2/pt active Search and Examination
- 2008-02-22 CN CN2008800125423A patent/CN101662949B/zh not_active Expired - Fee Related
- 2008-02-22 JP JP2009551045A patent/JP5285625B2/ja active Active
- 2008-02-22 US US12/528,362 patent/US20100137404A1/en not_active Abandoned
- 2008-02-22 WO PCT/US2008/054786 patent/WO2008118586A1/en active Application Filing
- 2008-02-22 CN CN200880012994A patent/CN101686711A/zh active Pending
- 2008-02-22 AU AU2008218176A patent/AU2008218176B2/en not_active Ceased
- 2008-02-22 WO PCT/US2008/054800 patent/WO2008103958A1/en active Application Filing
- 2008-02-22 US US12/528,158 patent/US20100143497A1/en not_active Abandoned
- 2008-02-22 BR BRPI0807790-8A patent/BRPI0807790B1/pt not_active IP Right Cessation
- 2008-02-22 ES ES08730572.8T patent/ES2546284T3/es active Active
- 2008-02-22 BR BRPI0807691A patent/BRPI0807691A2/pt not_active Application Discontinuation
- 2008-02-22 RU RU2009135231/13A patent/RU2436410C2/ru not_active IP Right Cessation
- 2008-02-22 CA CA2679008A patent/CA2679008C/en not_active Expired - Fee Related
- 2008-02-22 DK DK08730572.8T patent/DK2129237T3/en active
- 2008-02-22 JP JP2009551049A patent/JP5474571B2/ja active Active
- 2008-02-22 EP EP08780443A patent/EP2124610A1/en not_active Ceased
- 2008-02-22 WO PCT/US2008/054789 patent/WO2008103950A1/en active Application Filing
- 2008-02-22 US US12/528,153 patent/US20100104599A1/en not_active Abandoned
- 2008-02-22 WO PCT/US2008/054773 patent/WO2008103939A1/en active Application Filing
- 2008-02-22 CN CN200880012712A patent/CN101662950A/zh active Pending
- 2008-02-22 WO PCT/US2008/054796 patent/WO2008103956A1/en active Application Filing
-
2009
- 2009-09-14 ZA ZA2009/06390A patent/ZA200906390B/en unknown
- 2009-09-14 ZA ZA2009/06388A patent/ZA200906388B/en unknown
- 2009-09-14 ZA ZA2009/06389A patent/ZA200906389B/en unknown
- 2009-09-14 ZA ZA2009/06387A patent/ZA200906387B/en unknown
- 2009-11-30 ZA ZA2009/08481A patent/ZA200908481B/en unknown
-
2010
- 2010-09-07 US US12/876,451 patent/US9848622B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5286287B2 (ja) | 骨発達を促進するための組成物及び方法 | |
ZA200609861B (en) | Guanidino acetic acid used as an animal food additive | |
CA2829453A1 (en) | Compositions and methods for nutritional supplementation | |
JP2012152220A (ja) | 猫における甲状腺機能亢進症を予防する方法並びに限定されたセレン及びヨウ素を含む組成物 | |
BE1027481B1 (nl) | Voeder voor huisdieren omvattende een eiwitsamenstelling en werkwijze voor het produceren van genoemd voeder | |
MXPA01002440A (en) | Canine milk substitute |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101105 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20101105 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120330 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120628 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120705 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120730 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130502 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130603 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |